Sharing a Mounjaro pen — what you need to know before you consider it

You're staring at a pen with doses left — here's why passing it on is still the wrong call

Say you've just moved up to a higher strength. There are doses left in your old pen and it feels wasteful to discard them. Or perhaps a partner has been watching your progress and wonders whether one injection would do any harm. It's an understandable thought. Mounjaro is expensive, and the instinct to avoid waste makes complete sense.

The problem is structural, not just procedural. The Mounjaro KwikPen delivers tirzepatide through a fine internal needle channel. When you inject, a tiny amount of backflow can travel up that channel. Changing the outer needle does not flush or sterilise this pathway. A second person using the same pen body is therefore exposed to trace biological material from the first user, with no way to know what that means in practice. The risk of transmitting bloodborne infections including hepatitis B, hepatitis C and HIV is documented in clinical guidance on multi-dose pen devices generally, and it is why the NHS's own patient information on tirzepatide is explicit that pens must not be shared, even if the needle is replaced.

Beyond infection, there is the dose question. Mounjaro is titrated carefully per patient. Someone at week one of treatment needs 2.5 mg. Someone else using a pen already dialled partway through has no reliable way to confirm how many doses remain or whether the residual insulin-equivalent volume is accurate for their needs. Dosing errors with this class of medicine can cause significant gastrointestinal harm.

What the prescription actually covers, and why this matters legally

Mounjaro is a Prescription-Only Medicine under the Human Medicines Regulations 2012. That classification means a prescriber has assessed a specific individual and determined that this medicine, at this dose, is appropriate for them. The prescription names one patient. Supplying it to anyone else is not a grey area, it falls outside lawful supply.

This is worth sitting with for a moment, because online discussions sometimes frame sharing as a practical workaround for cost. It is not. The person receiving someone else's prescription has had no clinical review, no identity check, no assessment of contraindications. They may be on an interacting medicine. They may have a history that would make tirzepatide unsuitable. Understanding what Mounjaro is actually prescribed for helps explain why the assessment step exists in the first place, and why it cannot simply be skipped.

If cost is genuinely the concern, the context around Mounjaro pricing in the UK is worth reading, including what a legitimate private prescription actually covers when it comes from a properly regulated service.

Disposal and what to do with a pen you can no longer use

If your treatment has changed, your dose has been adjusted, or you have doses left in a pen you can no longer use, the right course is disposal through a sharps container rather than passing the pen to another person. Used and partially used pens should go into an approved sharps bin, never into a household bin or a recycling collection.

If you want to understand how storing your Mounjaro KwikPen correctly affects both safety and usability until the point of disposal, keep it refrigerated between 2°C and 8°C, away from direct light, and refer to the Patient Information Leaflet guidance on keeping your Mounjaro pen in use at room temperature for the right amount of time. If you are unsure about anything mid-treatment, including what to do with a pen you cannot continue using, our prescribers are reachable through aftercare seven days a week.

A sharps container rated for clinical waste is the safe route. If you need one, a 1-litre sharps bin is available through our pharmacy and can be disposed of via your local council's clinical waste collection or a pharmacy take-back scheme.

Getting your own treatment started properly

If someone in your life is asking to share your pen, the likeliest explanation is that they want access to tirzepatide but haven't yet found a route. The good news is that the process through a regulated service is faster than most people expect. There is no waiting list at a GP surgery to navigate, no referral required. A free consultation with a GPhC-registered prescriber at nume covers eligibility in a single same-day review.

Our prescribers review each consultation personally, not through an automated triage system. Our clinical team works to MHRA and GPhC standards, with photo-ID verification, live weight confirmation on video, and GP notification in line with current guidance. If someone is clinically suitable, their own pen arrives the next working day in plain packaging. That is the safe, legal, medically appropriate route, the only one worth taking.

Speak to our prescribers to check eligibility and start a consultation for yourself or point a friend in the right direction.